Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
tablet
extended-release tablet generic form sublingual tablet |
| gptkbp:brand |
Ambien
|
| gptkbp:chemicalFormula |
liver
C19H21N3O |
| gptkbp:commonName |
Intermezzo
10 mg 5 mg Edluar Zolpidem_Tartrate Zolpimist |
| gptkbp:contraindication |
severe liver impairment
history of substance abuse |
| gptkbp:duration |
6-8 hours
|
| gptkbp:endOfLife |
2.5 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zolpidem
|
| gptkbp:inheritsFrom |
15-30 minutes
|
| gptkbp:interactsWith |
CYP3A4 inhibitors
CYP3A4 inducers |
| gptkbp:isRecognizedFor |
children
pregnant women elderly patients nursing mothers |
| gptkbp:isTaskedWith |
alcohol
other CNS depressants |
| gptkbp:isUsedFor |
sedative-hypnotic
|
| gptkbp:lastProduced |
1992
|
| gptkbp:marketedAs |
Sanofi
|
| gptkbp:offersCoursesIn |
gptkb:Australia
gptkb:Canada gptkb:India gptkb:UK gptkb:USA |
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
dizziness
headache nausea drowsiness |
| gptkbp:symptoms |
anxiety
confusion irritability respiratory depression coma rebound insomnia |
| gptkbp:triggerType |
GABA_receptor_agonist
|
| gptkbp:usedFor |
insomnia
|